Lineage Cell Therapeutics, Inc. (AMEX:LCTX) went up by 18.00% from its latest closing price when compared to the 1-year high value of $1.67 and move down -41.53%, while LCTX stocks collected +29.67% of gains with the last five trading sessions. Press Release reported on 06/08/20 that Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen(R) in Dry AMD with Geographic Atrophy

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Worth an Investment?

Lineage Cell Therapeutics, Inc. (AMEX: LCTX) The 36 Months beta value for LCTX stocks is at 2.13, while of the analysts out of 0 who provided ratings for Lineage Cell Therapeutics, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $5.08 which is -$1.18 below current price. LCTX currently has a short float of 6.22% and public float of 140.87M with average trading volume of 868.28K shares.

LCTX Market Performance

LCTX stocks went up by 29.67% for the week, with the monthly jump of 28.26% and a quarterly performance of 36.24%, while its annual performance rate touched 16.83%. The simple moving average for the period of the last 20 days is 30.18% for LCTX stocks with the simple moving average of 30.41% for the last 200 days.

LCTX Stocks 40.37% Far from 50 Day Moving Average

After a stumble in the market that brought LCTX to its low price for the period of the last 52 weeks, Lineage Cell Therapeutics, Inc. was unable to take a rebound, for now settling with -29.34% of loss for the given period.

The stock volatility was left at 10.48%, however, within the period of a single month, the volatility rate increased by 10.18%, while the shares surge at the distance of +34.08% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +49.35% upper at the present time.

In the course of the last 5 trading sessions, LCTX went up by +29.67%, which changed the moving average for the period of 200 days to the total of +21.78% of gains for the stock in comparison to the 20-day moving average settled at $0.9215. In addition, Lineage Cell Therapeutics, Inc. saw 32.58% in overturn over the period of a single year with a tendency to cut further gains.

LCTX Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Lineage Cell Therapeutics, Inc. (LCTX), starting from Lineage Cell Therapeutics, Inc, who sold 2,383,090 shares at the price of $2.16 back on Jan 02. After this action, Rushing now owns 6,041,154 shares of Lineage Cell Therapeutics, Inc., valued at $5,137,942 with the latest closing price.

LCTX Stock Fundamentals

The current profitability levels are settled at -2423.07 for the present operating margin and -130.85 for gross margin. The net margin for Lineage Cell Therapeutics, Inc. stands at -792.22. Total capital return value is set at -33.96, while invested capital returns managed to touch -11.01. Equity return holds the value -50.60%, with -44.90% for asset returns.

Based on Lineage Cell Therapeutics, Inc. (LCTX), the company’s capital structure generated 4.58 points for debt to equity in total, while total debt to capital is set at the value of 4.37.

The value for Enterprise to Sales is 76.65 with debt to enterprise value settled at 0.05. The receivables turnover for Lineage Cell Therapeutics, Inc. is 0.10 with the total asset turnover at the value of 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.86.